Alkermes (Cencora / Lash Group)
Data Breach Class Action Lawsuit

May 22, 2024 -- Attention: victims of the Alkermes data breach.

Abington Cole + Ellery is investigating the data breach recently announced by Alkermes.

Alkermes data breach summary:

Unfortunately, at this time very little information is publicly available about the recently announced Alkermes data breach. A filing with the Attorney General of Texas on May 22, 2024, indicates that there was a data security breach affecting medical information of more than 700 Texans. According to information filed with the Attorney General of Texas, notice of the data security breach is being sent to affected consumers in Texas.

This data breach appears to be part of the recently announced Cencora / Lash Group data breach. It is not clear if notices regarding this breach will come from Cencora / Lash Group, or from Alkermes, or from both.

It is unclear if Alkermes is offering credit monitoring and/or identity theft protection services to affected individuals at this time. Data Breach notices being sent to affected individuals by Cencora / Lash Group include an offer for 24 months of free credit monitoring and/or identity theft protection services.

Hundreds of individuals were affected by the Alkermes data breach.

Breached data may include, but is not necessarily limited to: names, dates of birth, addresses, and medical data.

About Alkermes:

Alkermes is a biopharmaceutical company focused on developing innovative medicines for the treatment of central nervous system (CNS) diseases and cancer. The company's product portfolio includes proprietary medicines designed to address unmet medical needs and improve patient outcomes. Alkermes' research and development efforts are concentrated on small molecules, biologics, and new drug delivery technologies.

The company operates in the United States and Europe, with headquarters in Dublin, Ireland, and operations in Waltham, Massachusetts. Alkermes collaborates with academic institutions, government agencies, and other biopharmaceutical companies to advance its research and development programs. The company is committed to leveraging its expertise to bring new therapies to market, addressing complex and chronic conditions.

Alkermes' commercial product portfolio includes treatments for schizophrenia, bipolar I disorder, and opioid dependence. The company also has a pipeline of candidates in various stages of development, targeting diseases such as multiple sclerosis, major depressive disorder, and cancer. Through its ongoing research, clinical trials, and partnerships, Alkermes aims to contribute to the evolving landscape of biopharmaceuticals and improve patient care worldwide.

The Alkermes Website may have additional information about or provide periodic updates regarding the data breach.

For more information about steps you can take to possibly reduce the chances harm arising from a data breach, please review the following article: What are some steps you can take if you've been the victim of a data breach?

This website is not associated with nor authorized by Alkermes or any affiliated companies.